The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Michot Jean-Marie, Lappara Ariane, Le Pavec Jérôme, Simonaggio Audrey, Collins Michael, De Martin Eléonora, Danlos François-Xavier, Ammari Samy, Cauquil Cécile, Ederhy Stéphane, Barreau Emmanuel, Belkhir Rakiba, Berdelou Amandine, Lazarovici Julien, Chanson Philippe, Izzedine Hassan, Seferian Andrei, Le Pajolec Christine, Baldini Capucine, Martin-Romano Patricia, Mariette Xavier, Robert Caroline, Besse Benjamin, Hollebecque Antoine, Varga Andrea, Laghouati Salim, Mateus Christine, Voisin Anne-Laure, Soria Jean-Charles, Massard Christophe, Marabelle Aurélien, Champiat Stéphane, Lambotte Olivier
Аннотация
EXPERIMENTAL DESIGN: The ImmunoTOX assessment board was set up in 2016 at Gustave Roussy in France. It meets every 2 weeks to discuss the case-by-case management of patients presenting with irAEs. Here, we describe the ImmunoTOX board's activities between 2016 and 2019.
RESULTS: Over study period, 398 requests (concerning 356 patients) were submitted to the ImmunoTOX board. Most of the requests concerned the putative causal link between immunotherapy and the irAE (n = 148, 37%), followed by possible retreatment after temporary withdrawal because of an adverse event (n = 109, 27%), the clinical management of complex situations (n = 100, 25%) and the initiation of immunotherapy in patients with pre-existing comorbidities (n = 41, 10%). The ImmunoTOX board discerned 273 irAEs. The five organ systems most frequently involved by irAEs were lung (n = 58, 21%), gastrointestinal tract (n = 36, 13%), liver or biliary tract (n = 33, 12%), musculoskeletal system (n = 27, 10%), and nervous system (n = 23, 8%). The time to occurrence was shorter for severe irAEs (grade III and VI) than for mild irAEs (grades I and II), with medians of 47 and 91 days, respectively (p = 0.0216).
CONCLUSION: The main medical needs in the management of irAEs involved the lung organ. Severe irAEs were expected to occur earlier than mild irAEs. This real-life study can help to better estimate medical needs and therefore help to assess the management of irAEs.